Dr. Reddy's Laboratories Limited (RDY)
| Market Cap | 11.61B +3.6% |
| Revenue (ttm) | 3.85B +11.1% |
| Net Income | 629.75M +5.4% |
| EPS | 0.76 +5.6% |
| Shares Out | 832.57M |
| PE Ratio | 18.44 |
| Forward PE | 23.24 |
| Dividend | $0.07 (0.53%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 762,202 |
| Open | 13.48 |
| Previous Close | 13.72 |
| Day's Range | 13.41 - 13.55 |
| 52-Week Range | 12.77 - 16.17 |
| Beta | 0.30 |
| Analysts | Strong Buy |
| Price Target | 16.90 (+25.93%) |
| Earnings Date | May 12, 2026 |
About RDY
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i... [Read more]
Financial Performance
In fiscal year 2025, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.
Financial numbers in INR Financial StatementsAnalyst Summary
According to one analyst, the rating for RDY stock is "Strong Buy" and the 12-month stock price target is $16.9.
News
Canada gives nod for Dr Reddy’s semaglutide
Hyderabad: Dr Reddy's Labs said Wednesday that Health Canada has approved its generic semaglutide injection, making it the first company to secure mar.
Dr. Reddy's Laboratories Secures Health Canada Approval for Generic Semaglutide
Dr. Reddy's Laboratories Secures Health Canada Approval for Generic Semaglutide
Canada Approves Dr. Reddy's Generic Version of Novo Nordisk's Ozempic
The country is the first in the G7 forum to approve a generic version of the massively popular GLP-1 diabetes treatment.
Dr. Reddy's (RDY) Secures Approval for Generic Semaglutide in Canada
Dr. Reddy's (RDY) Secures Approval for Generic Semaglutide in Canada
Dr. Reddy’s Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada
Dr. Reddy’s becomes the first company to receive marketing authorization for generic Semaglutide Injection in Canada The market authorization was granted to Dr. Reddy’s ahead of Health Canada’s review...
Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada
HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $RDY #DrReddy--Dr. Reddy's Laboratories Ltd. announced that it has received a Notice of Compliance (NOC) from Health Canada for its generic...
Dr Reddy's Wins Nod to Sell Generic Ozempic, Check Cost Of Weight-Loss Drug
The entry of Dr Reddy's generic is triggering a price battle among pharmaceutical companies worldwide.
OneSource Pharma shares surge over 3% after partner gets approval for Semaglutide injection
Shares of OneSource Specialty Pharma Limited climbed over 3% in early trade after its strategic partner Dr. Reddy’s Laboratories received a Notice of Compliance from Health Canada for Semaglutide Inje...
Dr. Reddy's to announce Q4 and FY26 results on May 12, 2026
Dr. Reddy's Laboratories Ltd. is set to release its financial results for the fourth quarter and full year ending March 31, 2026, on Tuesday, May 12, 2026. The announcement will…
Why are Dr Reddy’s shares falling nearly 2% today? Explained
Shares of Dr Reddy’s Laboratories fell on Friday, April 24, after global brokerage Goldman Sachs downgraded the stock to ‘Sell’ from ‘Neutral’ and cut its target price to Rs 1,075,…
Broker Calls Today: Infosys Gets Mixed Bag, Dr Reddy's Downgraded, Cipla Bullish on Ventolin Approval — Full Analyst Roundup
A busy morning for broker calls with Infosys drawing the most divided analyst opinion after its Q4 FY26 results, Dr Reddy's receiving back-to-back downgrades on the Semaglutide opportunity, Cipla gett...
A Look at Dr Reddy's Laboratories Ltd (RDY) After 5.8% Gain -- GF Value $15.06 vs Price $13.58
A Look at Dr Reddy's Laboratories Ltd (RDY) After 5.8% Gain -- GF Value $15.06 vs Price $13.58
Dr. Reddy's (RDY) Stock Downgraded by Goldman Sachs
Dr. Reddy's (RDY) Stock Downgraded by Goldman Sachs
Dr. Reddy's (RDY) Shares Surge on Generic Drug News
Dr. Reddy's (RDY) Shares Surge on Generic Drug News
Nifty 50 top gainers today, April 23: Dr. Reddy's Laboratories, Cipla, Jio Financial Services, Adani Enterprises and more
Indian equity benchmarks ended lower on Thursday, April 23, 2026, with the NIFTY 50 closing at 24,173.05, down 205.05 points (-0.84%). Despite the broader market weakness, select stocks managed to…
Pharma stocks surge today, April 23: Dr. Reddy's Lab gains 6.43%, Strides Pharma rises 5.01%, Orchid Pharma surges 5.77%
Shares of pharmaceutical sector companies traded broadly higher on April 23, 2026, with Dr. Reddy's Laboratories, Strides Pharma Science, Orchid Pharma, and Glenmark Pharma among the standout gainers,...
Dr. Reddy's Laboratories shares surge 7% today, April 23: Details here
Shares of Dr. Reddy's Laboratories Limited rose over 7% on Thursday, April 23, trading against the broader market trend during the session. The stock opened at ₹1,230.00 against its previous…
Nifty 50 top losers today, April 21: SBI Life, Bharat Electronics, Dr. Reddy's Laboratories, Jio Financial Services and more
India’s benchmark indices ended higher on April 21, but a few heavyweights in the Nifty 50 closed in the red, reflecting selective profit booking across sectors. The Nifty 50 settled…
Torrent Pharma, Dr. Reddy’s and Zydus Life benefit as generic Semaglutide market share rises to 33% within 10 days of launch
The launch of generic Semaglutide in India has made an immediate and dramatic impact on the obesity and diabetes drug market, with CLSA’s latest healthcare channel check note revealing a…
Dr Reddy's board to consider final dividend for FY 2025-26
Dr Reddy's Laboratories will hold a board meeting to consider recommending a final dividend for the financial year 2025-26, the company disclosed in a regulatory filing on 16 April 2026.…
Pharma sector stocks surge today, April 15: Indoco Remedies up 5%, Orchid Pharma gains 4.04%, Dr. Reddy's falls 1.64%
Indian pharmaceutical sector stocks traded higher in early morning trade on Tuesday, April 15, 2026, with most counters advancing while Dr. Reddy's Laboratories remained an outlier on the downside. Am...
Dr. Reddy's Laboratories sells Svaas Wellness for Rs 2.23 crore
Dr. Reddy's Laboratories has announced the sale of its wholly owned subsidiary, Svaas Wellness Limited, for a total consideration of ₹2.23 crore. The agreement for the sale was finalised on…
Nifty 50 top losers today, April 7: Dr. Reddy's Laboratories, IndiGo, Adani Enterprises, Apollo Hospitals and more
Indian equity benchmarks closed higher on April 7, 2026, despite a volatile trading session, with the Nifty 50 ending above the 23,100 mark. However, selective profit booking was visible across…
Top gainers among Nifty 50 stocks in midday trades today, April 2: HCL Technologies up 1.1%, Dr. Reddy's Lab up 0.3%
IT stocks emerged as the top gainers among Nifty 50 constituents in midday trade on April 2, even as broader indices continued to trade lower during the session. As of…
Dr. Reddy's Laboratories issues 3,675 equity shares under ESOPs
Dr. Reddy's Laboratories has allotted 3,675 equity shares to eligible employees following the exercise of stock options under its Employees ADR Stock Options Scheme, 2007. The allotment took place on…